Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
Imatinib mesylate treatment is highly effective in chronic myeloid leukaemia and recent data have suggested that imatinib mesylate is also effective in the treatment of idiopathic hypereosinophilic syndrome (HES). Six patients with HES were treated daily with 100 mg imatinib mesylate. Five patients had normal karyotype and one showed trisomy 8. RT-PCR was negative for ETV6-PDGFRB and BCR-ABL fusion mRNAs. All patients rapidly achieved complete haematological remission. One patient remained in remission for more than 6 weeks after discontinuing treatment. No significant side effect was noted. Imatinib mesylate should be considered in the first-line therapy of idiopathic HES.
Salem
Ziad
Z
Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Zalloua
Pierre A
PA
Chehal
Aref
A
Bitar
Nizar
N
Abboud
Miguel
M
Kadri
Adel
A
Chami
Beatrice
B
Bazarbachi
Ali
A
D000328:Adult; D001483:Base Sequence; D001549:Benzamides; D002648:Child; D002898:Chromosomes, Human, Pair 8; D017931:DNA Primers; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D007621:Karyotyping; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014314:Trisomy
D001549:Benzamides; D017931:DNA Primers; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D020797:Receptor, Platelet-Derived Growth Factor beta; D016044:Fusion Proteins, bcr-abl